Giant Cell Arteritis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Giant Cell Arteritis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, MorphoSys AG, Hoffmann-La Roche, Sparrow Pharmaceuticals, Sint Maartenskliniek, Clearside Biomedical, Inc.

[Nevada, United States] - DelveInsight's "Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Giant Cell Arteritis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Giant Cell Arteritis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Giant Cell Arteritis Market Report:
The Giant Cell Arteritis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In October, 2024: Novartis Pharmaceuticals announced that the purpose of their study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica. The study will consist of an up to 4-week screening period, an up to 2-year Treatment Period which includes two Treatment Periods, and a 16-week treatment-free follow-up period (20 weeks post last dose of secukinumab).
In October, 2024: Novartis Pharmaceuticals announced that the purpose of their study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.
In July, 2024: Sparrow Pharmaceuticals announced that their study will be a single-blind, placebo-controlled phase 2 trial to compare prednisolone effects with and without SPI-62 in participants with PMR.
In February, 2024: AbbVie announced that their study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week 52, and to assess the safety and tolerability of upadacitinib in participants with giant cell arteritis (GCA).
As per the study conducted by DevauchellePensec et al. (2019), which used the EGB (Echantillon Généraliste des Bénéficiaires database found that prevalence of GCA in France is about 150 per 100,000
Catanoso et al. (2017) estimated the prevalence of GCA in Italy to be around 85 per 100,000 population.
According to a study by Castañeda et al. (2022), in Spain, it was reported that GCA mainly affects patients older than 50 years with a prevalence of30.4/100,000.
Key Giant Cell Arteritis Companies are as follows: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, MorphoSys AG, Hoffmann-La Roche, Sparrow Pharmaceuticals, Sint Maartenskliniek, Clearside Biomedical, Inc.
Key Giant Cell Arteritis Therapies are as follow: prednisone, mavrilimumab, Secukinumab, Prednisolone, Tocilizumab, Upadacitinib, Corticosteroid, SPI-62, Rituximab, Baricitinib
Launching multiple stage Giant Cell Arteritis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Giant Cell Arteritis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Giant Cell Arteritis Overview:
Giant Cell Arteritis (GCA), also known as temporal arteritis, is a type of vasculitis that primarily affects the arteries, especially those near the temples. It can lead to significant complications, including vision loss, if not promptly treated. The standard treatment for GCA involves the use of corticosteroids.

Giant Cell Arteritis Epidemiology Segmentation:
The Giant Cell Arteritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Giant Cell Arteritis Total Prevalent Cases
Giant Cell Arteritis Total Subtype-specific Cases
Giant Cell Arteritis Total Age group-specific Cases
Giant Cell Arteritis Total Clinical Manifestation-specific Cases

For more information about Giant Cell Arteritis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Giant Cell Arteritis Market Insights
Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis. It affects large and medium-sized blood vessels with a predisposition for the cranial branches derived from the carotid artery; in approximately 50% of cases, the aorta and its major branches may also be involved.

Giant Cell Arteritis Drugs Uptake
RINVOQ (upadacitinib), developed by AbbVie, is an orally administered selective and reversible JAK inhibitor, pro-inflammatory cytokines use immune signaling networks, such as the JAK-STAT pathway, to communicate with the cell nucleus.
COSENTYX (secukinumab), is an injectable fully human monoclonal antibody that specifically inhibits interleukin-17A (IL-17A), a cytokine involved in several immunological diseases, is being developed by Novartis Pharmaceuticals.
TREMFYA (guselkumab) is a human monoclonal antibody against the p19 subunit of interleukin (IL)- 23 developed by Janssen.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Giant Cell Arteritis Therapies and Key Companies:
prednisone, mavrilimumab: Kiniksa Pharmaceuticals, Ltd.
Secukinumab: Novartis Pharmaceuticals
Secukinumab, Prednisolone: Novartis Pharmaceuticals
Tocilizumab: Hoffmann-La Roche
Upadacitinib, Corticosteroid: AbbVie
SPI-62: Sparrow Pharmaceuticals
Rituximab: Sint Maartenskliniek

Giant Cell Arteritis Epidemiology:
Giant Cell Arteritis (GCA), also known as temporal arteritis, is a type of vasculitis that primarily affects individuals over 50 years of age. It is characterized by inflammation of the large and medium-sized arteries, particularly those in the head, and can lead to serious complications such as vision loss if not treated promptly. The following statistics provide an overview of the current epidemiology of GCA

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Giant Cell Arteritis Market Drivers:
Increasing Incidence and Awareness
Advancements in Diagnostic Techniques
Emerging Therapies and Research
Growing Understanding of GCA Pathophysiology

Giant Cell Arteritis Market Barriers:
High Treatment Costs
Limited Treatment Options
Challenges in Diagnosis
Potential Side Effects of Treatments

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Giant Cell Arteritis Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Giant Cell Arteritis Companies: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, MorphoSys AG, Hoffmann-La Roche, Sparrow Pharmaceuticals, Sint Maartenskliniek, Clearside Biomedical, Inc.
Key Giant Cell Arteritis Therapies: prednisone, mavrilimumab, Secukinumab, Prednisolone, Tocilizumab, Upadacitinib, Corticosteroid, SPI-62, Rituximab, Baricitinib
Giant Cell Arteritis Therapeutic Assessment: Current marketed and emerging therapies
Giant Cell Arteritis Market Dynamics: Giant Cell Arteritis Market drivers and Giant Cell Arteritis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Giant Cell Arteritis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Giant Cell Arteritis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Executive Summary of Giant-Cell Arteritis
4. Giant-Cell Arteritis Market Overview at a Glance
5. Disease Background and Overview
6. Diagnosis of Giant-Cell Arteritis
7. Diagnostic Guidelines
8. Treatment of Giant-Cell Arteritis
9. Treatment Guidelines
10. Epidemiology and Market Forecast Methodology
11. Epidemiology and Patient Population
12. Patient Journey
13. Marketed Therapies
14. Emerging Therapies
15. Giant-Cell Arteritis: Market Analysis
16. Unmet Needs
17. SWOT Analysis
18. KOL Views
19. Market Access and Reimbursement
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.